NDUFA5P11: A Potential Drug Target and Biomarker (G102724866)

Target Name: NDUFA5P11

NCBI ID: G102724866

NDUFA5P11

Other Name(s): NADH:ubiquinone oxidoreductase subunit A5 pseudogene 11

NDUFA5P11: A Potential Drug Target and Biomarker

NADH (nicotinamide adenine dinucleotide) is a crucial coenzyme found in all living cells that plays a vital role in energy metabolism. NAD+ is a dinucleotide, consisting of two nucleotides joined together, and is involved in many cellular processes, including energy production, redox reactions, and signaling pathways. One of the NAD+-dependent enzymes, NDUFA5P11 (NADH:ubiquinone oxidoreductase subunit A5 pseudogene 11), has been identified as a potential drug target and biomarker.

The NDUFA5P11 gene is located on chromosome 11p15 and encodes a protein involved in the NAD+-dependent ubiquinone oxidoreductase (UOR) pathway. This pathway is a critical route for the production of NAD+ from NADH, which is essential for many cellular processes, including energy metabolism, growth, and repair.NDUFA5P11 is a pseudogene, which means that it is a genetic variation in the original gene that has not been fully expressed.

Studies have shown that NDUFA5P11 is involved in various cellular processes, including the production of NAD+, protein synthesis, and cell survival. NDUFA5P11 is also involved in the detoxification of harmful substances, such as drugs and other environmental toxins, which can cause oxidative stress in cells.

As a potential drug target, NDUFA5P11 has been studied for its potential therapeutic effects. Studies have shown that inhibiting NDUFA5P11 activity can increase NAD+ levels in cells, which can have a beneficial effect on cellular processes. For example, increasing NAD+ levels has been shown to enhance the sensitivity of cancer cells to chemotherapy drugs, leading to a more effective treatment.

In addition to its potential therapeutic effects, NDUFA5P11 has also been shown to be a potential biomarker for a variety of diseases, including cancer, neurodegenerative diseases, and cardiovascular diseases. The NAD+-dependent ubiquinone oxidoreductase pathway is a critical pathway for the production of NAD+, which is involved in many cellular processes that are affected by a wide range of diseases. Therefore, studying NDUFA5P11 is important for understanding the underlying mechanisms of these diseases and developing new treatments.

In conclusion, NDUFA5P11 is a promising drug target and biomarker that has the potential to improve the treatment outcomes for a variety of diseases. Further research is needed to fully understand the role of NDUFA5P11 in cellular processes and to develop new treatments based on this information.

Protein Name: NADH:ubiquinone Oxidoreductase Subunit A5 Pseudogene 11

The "NDUFA5P11 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about NDUFA5P11 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets